Medicine and Dentistry
Patient
100%
Therapeutic Procedure
42%
Ribavirin
29%
Hepatitis C Virus
19%
Infection
18%
Liver Cirrhosis
16%
Transplantation
16%
Combination Therapy
16%
Genotype
15%
Adverse Event
12%
Antivirus Agent
12%
Donor
11%
Liver Transplantation
11%
Inpatient
10%
Nonalcoholic Fatty Liver
10%
Simeprevir
10%
Peginterferon
9%
Hepatitis C Virus Genotype 1
9%
Liver
9%
Ritonavir
8%
Liver Graft
7%
Placebo
7%
Fibrosis
7%
Chronic Hepatitis C
6%
Organ
6%
Ombitasvir
6%
Cimetidine
6%
Decompensated Liver Cirrhosis
5%
Adult
5%
Hepatocellular Carcinoma
5%
Clearance
5%
Paritaprevir
5%
Hepatitis C
5%
Interferon
5%
Cells
5%
Analysis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
38%
Infection
24%
Liver Cirrhosis
23%
Hepatitis C Virus
21%
Adverse Event
16%
Antivirus Agent
13%
Peginterferon
12%
Hepatitis C Virus Genotype 1
11%
Nonalcoholic Fatty Liver
10%
Simeprevir
10%
Chronic Hepatitis C
9%
Ritonavir
8%
Sofosbuvir
7%
Glecaprevir Plus Pibrentasvir
7%
Boceprevir
6%
Ombitasvir
6%
Fibrosis
6%
Interferon
6%
Drug
6%
Cimetidine
6%
Hepatitis C
6%
Daclatasvir
6%
Paritaprevir
6%
Colchicine
5%
Decompensated Liver Cirrhosis
5%
Liver Cell Carcinoma
5%
Dasabuvir
5%
Nursing and Health Professions
Patient
53%
Ribavirin
24%
Inpatient
21%
Liver Cirrhosis
18%
Infection
15%
Sustained Virologic Response
15%
Transplantation
11%
Combination Therapy
11%
Peginterferon
8%
Adverse Event
8%
Liver Transplantation
7%
Procedures
7%
Chronic Hepatitis C
6%
Placebo
6%
Simeprevir
5%
Antivirus Agent
5%
Ritonavir
5%
Glecaprevir Plus Pibrentasvir
5%